Costly Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis
Photo Credit: Jelina Preethi MASH’s economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of cirrhosis. Metabolic dysfunction–associated steatohepatitis (MASH), previously known as nonalcoholic …